|
Generic Name |
capromorelin |
|
Indication |
ENTYCE™: Anorexia (dogs) ELURA™: Management of Weight Loss with CKD (cats) |
|
Seller |
Elanco Animal Health, Inc. (U.S.) |
ENTYCE™ and ELURA™ are drugs for companion animals developed with capromorelin, a ghrelin receptor agonist, as the active pharmaceutical ingredient whose rights were transferred from Pfizer Inc. when RaQualia Pharma was established. It was developed by the licensee Aratana Pharmaceuticals in the U.S. (now Elanco), and ENTYCE™ was first approved by the FDA as the only drug for appetite stimulation in dogs, followed by ELURA™ for weight loss management in cats with chronic kidney disease.
Loss of appetite in companion animals is a symptom that appears with various diseases, and is an important sign not only of weight loss but also of shorter life expectancy if left untreated.
Currently, ENTYCE™ is marketed in the U.S. and ELURA™ in the U.S., France and Japan, with further progress expected in other regions.